SKP2 overexpression has been already described in BrCa and PCa, contributing to the development and proliferation of these tumors, the acquisition of a mesenchymal phenotype, and the resistance to radio- and chemotherapy [87,88,89,90], being a potential therapeutic target [73]. This evidence concerns the gene SKP2 and posterior cortical atrophy.